Stephanie Strobl-Kacerovsky
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial.
Journal: Breast (Edinburgh, Scotland)
Published: May 05, 2025
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34.
Journal: Breast (Edinburgh, Scotland)
Published: January 29, 2025
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.
Journal: Cancer communications (London, England)
Published: August 01, 2024
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 09, 2023
Explaining risks and benefits of loco-regional treatments to patients.
Journal: Breast (Edinburgh, Scotland)
Published: July 10, 2023
Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).
Journal: Virchows Archiv : an international journal of pathology
Published: March 14, 2023
Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.
Journal: NEJM evidence
Published: December 01, 2022
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 31, 2022
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Journal: The New England journal of medicine
Published: July 28, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026